tbuckley/cabot-search huggingface dataset:
An International Multi-Institutional Study of Double Cord Blood Transplantation in a Racially Diverse Population.
Authors: Karen Ballen, Brian Wang, Joseph Rosenthal, Auayporn Nademanee, Chatchada Karanes, Tang-Her Jaing, Michael Graham, Patrick Tan, David Gjertson, Lawrence Petz, Stephen Forman, Robert Chow
Journal: Blood (2007)
Early stages of clear cell (glycogen rich cell) invasive ductal carcinoma (IDC) of the breast: Good or bad prognosis?
Authors: M. J. Nacul, C. Garcia Gerardi, H. Japaze, E. Gil Deza, N. Gercovich, C. Diaz, M. Russo, B. Rolnik, F. Tognelli, E. L. Morgenfeld, E. G. J. Rivarola, F. G. Gercovich
Journal: Journal of Clinical Oncology (2011)

e11053 Background: The presence of clear cells (glycogen rich cells) in invasive ductal carcinoma of the breast is infrequent. The main objective of the present paper is to analyze the frequency of this tumor subtype in our patient group. Methods: A search of the IOHM breast cancer tumors registry was carried out. In this database all 1680 tumors were reviewed by two pathologists and classified according to the USA Association of Directors of Anatomic and Surgical Pathology’s recommendations. The entire cohort was diagnosed, treated and followed at the IOHM. Only those with early stages of clear cell (glycogen rich cell) invasive ductal carcinoma of the breast were included in this paper. Results: Between January 1998 and June 2008, 945 patients with IDC and early breast cancer were identified. 17 (1,8%) of those cases presented clear cell carcinomas, and are the subject of this report. Population Characteristics: Median Age 60 years (35-88); Menopause YES/NO 11/6; High Tumor Grade 15; Predictive Factors: ER (+):=15/17, PR (+)= 13/17, Her2 (+) 2/6 (Undetermined 11 cases), Diagnosis Stage (I=6 pts, II=5 pts, III=6 pts); Surgery: Mastectomy= 3 pts, Tumorectomy= 14pts, Radiotherapy=16 pts, Adjuvant treatment: 17 pts (Only Hormonotherapy: 7 pts, Only Chemotherapy: 5 pts, Chemotherapy and hormonotherapy: 5 pts) With a median Follow Up of 97 months (27-146), twelve patients are alive and free of disease (Stage I: 6 pts, Stage II : 4 pts, Stage III: 2 pts), Four patients have recurred (Stage II: 1 pt, Stage III: 3 pts) and four have died : 3 due to the tumor and 1 due to other causes, with a global median survival of 92 months (range 16-146). In each stage, the median survival is Stage I: 86 months (44-145), Stage II: 114 months (30-129), Stage III: 69 months (16-106). Conclusions: 1) In this cohort 1.8% of patients with early IDC breast cancer possess clear cells associated with the tumor. 2) Although the number of patients is low, the evolution was better than that observed in patients with High Tumor Grade IDC at similar stages. 3) It appears that the presence of glycogen rich cells is not a factor leading to a bad prognosis.
Postoperative versus preoperative chemoradiotherapy in locally advanced rectal cancer patients.
Authors: H. F. EL-Shazly., G. Schlimok, A. F. Barakat, L. A. Korashy, N. M. El Mashad
Journal: Journal of Clinical Oncology (2011)

e14156 Background: Postoperative chemo-radiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative with postoperative chemo-radiotherapy for locally advanced rectal cancer patients. Methods: 84 patients with locally advanced resectable rectal cancer (clinical stage T3 or T4 or node-positive disease), 44 from them received neo- adjuvant radio-chemotherapy (Group I) before surgical resection versus 40 locally advanced rectal cancer patients received adjuvant radio-chemotherapy then chemotherapy after surgical resection (Group II). Statistical analysis of treatment response, duration of disease free, time to progression, survival rates, treatment tolerability and toxicity. Results: There is no statistically significant difference between rectal cancer patients as regard either survival function or disease recurrence. The overall three-year survival rates OS were 95.5 % (Group I) and 95 % (Group II), respectively (P=0.638). The disease free three-year survival rates DFS were 75% (Group I) and 70 % (Group II), respectively (P=0.908). The three-year cumulative incidence of local relapse was 25 percent for patients assigned to preoperative chemo-radiotherapy and 30 percent in the postoperative-treatment group (P=0.63). After preoperative chemo-radiotherapy, there is a significant shift toward earlier TNM stages (P=0.002) tumour with down staging. Conclusions: Preoperative as compared with post operative chemo-radiotherapy has a significant down staging given that it is associated with a superior overall compliance rate, an improved rate of local control, reduced toxicity, and an increased rate (66 %) of sphincter preservation in patients with low-lying tumours but did not improve survival rate.
Final results from a choice based conjoint study assessing patient preferences for selected features of erythropoietic agents
Authors: S. Bolge, J. Fastenau, J. Howell, C. T. Piech, J. Donohue
Journal: Journal of Clinical Oncology (2005)

8248 Background: Early results from a choice based conjoint study (CBC) assessing patient preferences for selected attributes of erythropoietic agents suggest providers and patients both view effectiveness as more important than convenience. (Bolge SC et al. Blood. 2004;104:412b (5307)) This analysis focuses on the final data. Methods: Information was collected from providers and their adult anemic patients with solid tumors via a two-part, self-administered questionnaire at the time of a scheduled encounter. The first part was completed by providers and captured their beliefs regarding patient preference for anemia medication and related clinical information. The second part was completed by patients and elicited their preferences and experience with anemia management. Two attributes were evaluated in the CBC. One was effectiveness, defined as time to a noticeable relief of fatigue in 4, 6, or 8 weeks. The other was convenience, defined as 4, 6, or 8 provider visits in an 8-week period. Results: 500 provider/patient-matched questionnaires were received from 50 oncology practices. 467 providers and 438 patients completed the CBC (93% and 88% response rates, respectively). 77% of providers viewed time to a noticeable relief of fatigue as being more important to patients than frequency of visits when choosing a medication to treat anemia. Similarly, patients viewed time to a noticeable relief of fatigue as being the more important characteristic of anemia medications (1.9 times more important than frequency of visits). For time to a noticeable relief of fatigue, patients prefer an early onset (4 over 6 over 8 weeks). For convenience, patients prefer 8 over 6 over 4 visits during an 8-week period. Conclusion: Final results from the CBC are consistent with previously reported interim findings. Both providers and patients view effectiveness as a more important attribute of anemia treatment than convenience. While patients prefer relief of fatigue as soon as possible, interestingly, their preference to see providers more frequently rather than less may be contrary to some providers’ beliefs. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ortho-Biotech Clinical Affairs, LLC Ortho-Biotech Clinical Affairs, LLC
Effect of Onco<i>type</i> DX colon cancer test results on treatment recommendations in patients with stage II colon cancer: Preliminary results.
Authors: Thomas H. Cartwright, Calvin Chao, Margarita Lopatin, Tanya GK Bentley, Michael Samuel Broder, Eunice Chang
Journal: Journal of Clinical Oncology (2012)

398 Background: The Oncotype DX Colon Cancer Recurrence Score (RS) has been clinically validated as an independent predictor of individual recurrence risk in stage II colon cancer patients following surgery. As a result, physicians have been ordering the Oncotype DX assay for stage II colon cancer patients since January 2010, yet no data exist on the assay’s impact on adjuvant treatment planning in practice. We performed a survey to characterize the impact of the assay on adjuvant treatment recommendations in stage II colon cancer. Methods: U.S. medical oncologists (N=277) who ordered Oncotype DX for ≥3 patients with stage II colon cancer were contacted and asked to complete a web-based survey regarding the single most recent stage II colon cancer patient for whom the assay was ordered. The survey was developed through cognitive interviews with four medical oncologists, and the protocol was institutional review board approved. Results: As a planned preliminary analysis, we analyzed surveys from 92 eligible physicians. Physicians were more often in community (85%) than academic or other practices, and had a median of 14.5 years (range, 2-40) of practice experience. The median patient age was 62 years (range, 34–81). 84% of patients had T3 disease. Patients had ≤8, 9-11 and ≥12 nodes examined 2%, 14% and 84% of the time and 36% had comorbidities. Of the 60 patients tested for MMR/MSI, 9 (15%) were MMR-D or MSI-high and 37 (62%) were MMR-P or MSI-low; 14 (23%) unknown. Median RS was 20 (range, 1-77). Before obtaining the RS, chemotherapy was planned in 38 (41%) patients, observation in 35 (38%), and there was no recommendation in 19 (21%). For the 73 patients with pre-assay recommendations, recommended treatment changed after obtaining the RS for 23 patients (32%), including changes from chemotherapy to observation and vice-versa. Conclusions: These preliminary findings indicate that for stage II colon cancer patients, treatment recommendations were changed by RS results approximately one-third of the time. Final results will be reported to include accrual through December 2011.
Expression of S100 proteins in normal human hematopoietic stem cells and in AML
Authors: H. Lannert, M. Lenze, T. Able, A. Lenze, R. Saffrich, V. Eckstein, S. Leicht, X. Li, T. Franz, A. D. Ho
Journal: Journal of Clinical Oncology (2008)

7072 Background: In the quest to reduce mortality and morbidity from cancer, there is continued effort to identify novel biomarkers to aid in the early detection and the accurate prediction of tumour behaviour. One group of proteins that is emerging as a potentially important group of markers in multiple tumour types is the S100 family of calcium-binding proteins. There is increasing evidence that altered expression of S100 family members is seen in many cancers including breast, lung, bladder, kidney, thyroid, gastric, prostate and oral cancers. S100 proteins are commonly up-regulated in tumours and this is often associated with tumour progression. We focused our expression- investigations on different subsets of highly enriched CD34+ stem cells from different human origins: cord blood (CB), bone marrow (BM), as well as CD34+ leukemia cells (AML M2), thus e.g. to identify new protein targets for leukemia therapy. Methods: Mononuclear cells were isolated by a standard Ficoll-Hypaque gradient separation method from the different blood sources. An Auto-MACS (Miltenyi) and FACS Vantage SE cell sorter (Becton Dickinson) was used to highly enrich (>99%) CD34+ cells fractions. Sample preparation: Total RNA was isolated from sorted 1 x 10e6 cells by standard methods using RNA isolation kit (Qiagen). For gene expression analysis topic-defined PIQOR™ stem cell microarrays (936 genes) were performed. The quantitative proteinexpression was analyzed by western blotting. The subcellular localizations of the identified proteins were performed by fluorescence and confocal microscopy of all cell fractions. Results: 1. Significant mRNA overexpression of S100A10 and S100A11 in microarray analysis correlates directly to the protein overexpression in AML. 2. There was a translocation of S100A11 expression from exclusively nuclear in human stem cells to cytoplasmic and nuclear in AML cells. Conclusions: S100A10 and S100A11 are overexpressed in AML. In addition, S100A11 undergoes a nucleocytoplasmic translocation which may have a direct influence on the proliferation of the AML cells. S100A10 and S100A11 have been suggested to have potential roles in carcinogenesis and tumour progression but their expression has not been described before in human hematopoietic stem cells and AML cells. No significant financial relationships to disclose.
Transcatheter arterial embolization (<i>TAE</i>) combined with recombinant adeno-viral human p53 genein treatment of patients with unresectable hepatocellular carcinoma (HCC).
Authors: Y. Zhang
Journal: Journal of Clinical Oncology (2011)

e14521 Background: To evaluate the response rate and safety of TAE combined with rAd-p53 in treatment of unresectable HCC. Methods: Patients with unresectable HCC affecting one lobe, and with Child-Pugh score A or B, was treated by TAE combined with rAd-p53. The tumor artery was embolized using Gelatin sponage particles(GSPs) with a diameter of 350-560 µm, which degrade in 14 days. The 1-4×1012 rAd-p53 viral particles (VP) diluted in 10 ml of saline solution was mixed with GSPs. The study endpoints were liver function, adverse effects, and response rate. Results: Fifteen patients received 1-2 times of TAE plus rAd-p53 in two months. After 3-5 days of treatment, CT scan showed deceased tumor density in all these cases and gas formation inside of tumor in 6 cases. Three months after the first time of treatment, CT scan showed three cases achieved a complete response (CR), nine partial response (PR) and three stable disease(SD). The response rate was 80%. The average reduction in tumer diameter was 72.5%. Liver function restored to normal level in 7-10 days after treatment. Fever was observed in all case. No severe complications, such as cholantitis or liver abscess were observed. Conclusions: GSPs embolization combined with rAdp53 was safe and effective in the treatment of unresectable HCC. Response rate is much higher than GSPs embolization alone, which was 48% based on historical data.
Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer: A European multicenter phase II trial.
Authors: F. Levi, M. Bouchahda, M. Ducreux, A. Karaboué, C. N. Focan, P. Rougier, P. Innominato, D. Smith, S. Awad, R. Adam
Journal: Journal of Clinical Oncology (2010)

TPS198 Background: Circadian clocks control drug metabolism and cell cycle over the 24 h in healthy liver and are disrupted in cancer cells (Lévi et al. Annu Rev Pharm. Toxicol 2010). Hepatic artery infusion (HAI) of chronomodulated (chrono) irinotecan, 5-FU and oxaliplatin offered a first proof of principle of improved therapeutic index in patients (pts) with liver metastases from colorectal cancer (mCRC) failing 3 prior chemotherapy (chemo) lines (Bouchahda et al. Cancer 2009). Intravenous cetuximab (iv cetux) addition could further enhance efficacy of HAI in pts with predominantly hepatic mCRC with wt K-Ras, through allowing complete macroscopic resections of metastases. Methods: This is among the first international trials specifically targeting liver mCRC for enhancing the rate of complete macroscopic resections. It is an open label nonrandomized strategic phase II study of iv cetux and HAI of irinotecan (180 mg/m2), 5-FU (2,800 mg/m2), and oxaliplatin (85 mg/m2) q 2-wks. The primary objective_is to increase from 15% to 30% the complete macroscopic resection rate of liver mCRC. Chemo is given as chrono or conventional infusion, according to institution. Secondary endpoints include the rates of pathologic complete responses, and relapses, and usual efficacy (RECIST) and toxicity (NCIC v3.0) criteria. Eligible patients received 1-3 prior chemo lines for mCRC, deemed as non resectable with curative intent in multidisciplinary staff meeting (<30% estimated residual liver after resection; prior progressive disease). Pts undergo partial hepatectomy after 3-9 courses whenever possible. Translational studies include a pharmacokinetic analysis of all drugs during 1st course (16 pts), a monitoring of cytokines and rest-activity rhythm at baseline, and during 1st and 4th course, and a genetic study in host and tumor cells for assessing clock and pharmacology gene determinants. Current status:21 of 60 expected pts are registered at 6 centers. Adequate safety in the initial 6 pts on each schedule led the French Agency (AFSSAPS) to let the trial proceed. Efficacy data are expected in March 2011. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck Serono, Pfizer
National guidelines for the best practices in palliative and end-of-life care for lesbian, gay, bisexual, and transgender cancer patients and their families.
Authors: Shail Maingi, Sean O'Mahony, Michael G Bare, Liz Margolies, Nfn Scout, Charles Stewart Kamen
Journal: Journal of Clinical Oncology (2015)

126 Background: A growing body of evidence indicates that LGBT communities are disproportionately affected by cancer due to higher rates of traditional risk factors such as tobacco and alcohol, non-inclusion in educational campaigns, and minority stress. Due to the exclusion of sexual orientation and gender identity measures in national oncology databases, there has been difficulty documenting the extent of healthcare disparities that exist for LGBT cancer patients. However, an increasing number of studies describe the experiences of LGBT patients and their families at the end of life. Although societal attitudes and legal protections are shifting, the existing literature clearly indicates that LGBT patients in palliative and end-of-life care settings encounter unique barriers to quality care. For example, LGBT individuals may distrust specific members of palliative care teams, such as a pastor because of past rejections by faith-based communities. Other barriers include high levels of familial rejection, fear of revealing minority status, and a lack of legal protection. Methods: In 2014 and 2015, a CDC-funded multidisciplinary expert panel met to develop the best practices across the cancer care continuum for the LGBT community. The experts drew on available literature and clinical and community experience. They reached a consensus regarding recommendations that were later reviewed using a process that elicited comments from providers, patients, and community and national organizations. Results: Recommendations were made in 7 domains: 1) cancer prevention, 2) cancer screening, 3) diagnosis, 4) treatment, 5) survivorship, 6) palliative and end-of-life care, and 7) public health. Here we report the panel’s recommendations for improving palliative and end-of-life care for LGBT cancer patients. Conclusions: The barriers for LGBT cancer patients to access quality palliative and end-of-life care exist, and the subsequent healthcare disparities are often invisible to healthcare providers. Implementation of these national recommendations will help eliminate the disparities that LGBT patients and their families experience when facing cancer.
The correlation of neutrophil/lymphocyte ratio and tumor reduction ratio in preoperative chermoradiotherapy for advanced rectal cancer.
Authors: Koji Yasuda
Journal: Journal of Clinical Oncology (2014)

633 Background: Preoperative chemoradiotherapy (CRT) is widely used for the treatment of advanced lower rectal cancer and is considered to reduce the local recurrence rate and improve the anus preservation rate. However, the tumor reduction effect varies among patients, and thus far, no factor has yet been found to be effective in the prediction of therapeutic efficacy. Recent studies have shown tumor immunity in the tumor microenvironment to be involved in the anti-tumor effect of radiation and anti-cancer drugs. Among these studies, some show that the neutrophil/lymphocyte (NL) ratio in blood test results correlates with the therapeutic efficacy. We examined the correlation between the NL ratio based on blood test results and tumor-reducing effect of preoperative CRT on advanced lower rectal cancers. Methods: We included 30 advanced lower rectal cancer patients who underwent preoperative CRT during the period ranging from January 2008 to June 2013.For advanced lower rectal cancers classified as cT3orT4NXM0, preoperative CRT was conducted according to the following regimen: 50.4 Gy (1.8 Gy × 28 fr) + UFT (300 mg/day, LV [75 mg/day]) × 28 days. The neutrophil count and lymphocyte count were determined based on the blood tests conducted before and after CRT; the NL ratio was calculated, and the correlation between the value of the ratio and tumor reduction rate was examined. Results: Radical surgery was performed on 28 of the 30 patients who underwent preoperative CRT. One of the 28 patients showed local recurrence (rate, 3.6%). In addition, down stage tumors were found in 16 of the 28 patients, and the down stage rate was 57.1%. Significant differences (p &lt; 0.0001) were found between the tumor reduction effect and NL ratio from blood tests before CRT, as well as between the tumor reduction effect and the ratio from blood tests after CRT. Conclusions: The above findings suggest anti-tumor immunity in the tumor microenvironment, particularly that lymphocytes might be involved in the antitumor effectiveness of preoperative CRT in advanced lower rectal cancers. In addition, NL ratio from blood tests could be a predictive factor of the tumor reduction effect.
The financial burden of unexpected hospitalizations for childhood cancer patients and their families.
Authors: Anne C. Kirchhoff, Echo L. Warner, Mark Fluchel
Journal: Journal of Clinical Oncology (2013)

267 Background: Complications of therapy, such as infection, pain, or dehydration, may cause financial stress for childhood cancer patients due to unexpected hospitalizations. Treatment for childhood cancer is typically provided at tertiary health care centers, requiring rural patients to travel long distances for care. We evaluated the perceived financial burden of unanticipated hospitalizations, insurance, and rurality on childhood cancer patients and their families. Methods: A single-site, cross-sectional survey of primary caretakers of childhood cancer patients was performed from July 2010-July 2012. Eligible patients were treated at a pediatric cancer hospital, diagnosed age ≤21 years and were ≤5 years from diagnosis (N=310). Financial burden was rated on a visual analog scale of 0-100. Multivariable linear regression models were used to calculate coefficients and 95% Confidence Intervals (CI) of financial burden by number of unexpected hospitalizations (0, 1-4, ≥5) and time since diagnosis. Results: The average age at diagnosis was 7.0 (SD 5.6) years. The most common diagnosis was leukemia (47.4%). The mean number of unexpected hospitalizations was 4.2 (SD 7.3). Patients did not differ on number of unexpected hospitalizations by current age, gender, race/ethnicity, or household income. In multivariable analyses, patients 1-5 years past diagnosis with ≥5 unexpected hospitalizations reported financial burden was 22.6 (95% CI 6.2-39.1, p=0.007) points higher than those with no hospitalization and 13.7 (95% CI 2.8-23.6 p=0.007) points higher than those with 1-4 hospitalizations. Patients &lt;1 year from diagnosis did not differ. While type of insurance (public vs. private) did not impact burden, rural patients reported 15.0 (95% CI 6.8-23.2, p&lt;0.001) points higher financial burden than urban patients. Conclusions: A high number of unexpected hospitalizations and rural residence were associated with greater financial burden for families of childhood cancer patients. Efforts to reduce unexpected admissions by managing side effects in outpatient visits, utilizing home health nurses and collaborating with local primary care physicians for remote patients could help ease the financial burden.